Mechanistic description
Dysbiotic bacteria compromise intestinal barrier integrity through zonulin pathway activation, allowing bacterial antigens and α-synuclein oligomers to enter systemic circulation and seed CNS pathology. Targeted tight junction stabilizers could prevent this peripheral-to-central disease propagation.
Evidence for (5)
Macrophage-derived CTSS drives the age-dependent disruption of the blood-CSF barrier.
Claudin-1 interacts with EPHA2 to promote cancer stemness and chemoresistance in colorectal cancer.
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Streptococcus pneumoniae extracellular vesicles aggravate alveolar epithelial barrier disruption via autophagic degradation of OCLN (occludin).
Benvitimod Inhibits IL-4- and IL-13-Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes.
Evidence against (2)
The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence.
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions.